



Scientists and Health Care Workers
Committed to HIV/AIDS

4th International AIDS Society Conference on HIV Pathogenesis and Treatment

Sydney, Australia - July 22 - 25, 2007

INCREASED VIRAL SET POINT FOLLOWING IL-15 TREATMENT OF ACUTE SIV INFECTION

IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOAA104

Katsikis P.¹, Mueller Y.¹, Do D.¹, Altork S.¹, Katsetos C.¹, Legido A.¹, Villinger F.², Altman J.¹, Lewis M.³

¹Drexel University College of Medicine, Philadelphia, United States, ²Emory University School of Medicine, Atlanta, United States, ³BIOQUAL, Rockville, United States

OBJECTIVES: To test the immunologic, virologic and clinical effect of in vivo treatment of acutely SIV infected non-human primates with the pleiotropic cytokine IL-15.

METHODS: Mamu-A*01+ rhesus macaques were treated during acute SIV infection with IL-15. Animals received 100µg/kg body weight IL-15 ($n=6$) or saline ($n=6$) twice a week for 4 weeks following SIV infection. Peripheral blood and lymph node biopsies were evaluated weekly for SIV-specific CD8+ T cells, lymphocyte subpopulations and viral loads.

RESULTS: Beyond week 3 post-infection IL-15 treated animals exhibited progressively higher blood viremia that reached $43\pm 29\times 10^6$ SIV RNA molecules/ml blood at week 20 compared to $2.4\pm 0.9\times 10^4$ SIV RNA molecules/ml in untreated animals. At weeks 25-26, 2 out of 6 IL-15 treated animals developed simian AIDS and were euthanized with one animal exhibiting early 'minimal lesion' SIV meningoencephalitis. IL-15 treated animals had a 2-fold increase in peripheral blood Gag- and Tat-specific CD8+ T cell and NK cells numbers at day 14 compared to controls with no further differences seen at later time points. CD8+ T cell numbers were also increased by 2-fold in IL-15 treated animals during the course of IL-15 treatment up to week 4. IL-15 treatment significantly decreased the percentage of HLA-DR+Gag-specific CD8+ T cells in blood but increased lymph node numbers of Gag-specific CD8+ T cells by 3 fold at week 30. No differences were found for CD4+ T cells, monocytes and B cells. An increase in percentage of Ki-67+CD4+ T cells was observed at week 1 with 20% in IL-15 treated compared to 10% in untreated animals. CCR5+CD4+ T cells were nearly absent from the blood of IL-15 treated animals after week 3.

CONCLUSIONS: These data show that IL-15 administration during acute SIV infection leads to dramatically increased viral set points and accelerates progression to AIDS.

This study was supported by grant NIH R01 AI46719 and AI62437.

2007-07-22

MOAA104

Immune Activation in HIV Pathogenesis

Copyright © 2007 - [International AIDS Society](#) (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted grants from [Boehringer Ingelheim](#), [Bridgestone/Firestone Charitable Trust](#), [Bristol-Myers Squibb Company](#), [Elton John AIDS Foundation](#), the [National Library of Medicine](#), and [donations](#) from users like you. **Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.**

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. **Always discuss treatment options with a doctor who specializes in treating HIV.**

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.